论文部分内容阅读
目的:探讨常规治疗急性脑梗死和加用依达拉奉治疗急性脑梗死的疗效变化。方法:200例急性脑梗死随机分为治疗组和对照组,每组各100例,对照组用常规治疗方法(丹参或参麦和胞二磷胆碱静脉滴注,口服阿司匹林等治疗),治疗组在常规治疗的基础上加用依达拉奉注射液,3 d后进行疗效评定。结果:1周后治疗组、对照组ESS评分分别为70.38±16.32、64.4±14.45,3周后治疗组、对照组ESS评分分别为82.4±13.8、76.9±13.8,两组对比有统计学差异。而从治疗组和对照组的起效时间相比,治疗组明显早于对照组,差异统计学意义。结论:依达拉奉注射液30 mg静脉滴注,2次/d治疗,能有效改善急性脑梗死的神经功能缺失和日常生活能力,并能好地控制脑梗死的进展。
Objective: To investigate the curative effect of conventional treatment of acute cerebral infarction and edaravone in the treatment of acute cerebral infarction. Methods: 200 cases of acute cerebral infarction were randomly divided into treatment group and control group, with 100 cases in each group. Patients in control group were treated with conventional treatment (Salvia miltiorrhiza or Shenmai and Citicoline intravenous drip, oral aspirin, etc.) Group based on conventional treatment plus edaravone injection, 3 d after the curative effect evaluation. Results: After 1 week, the ESS scores of the treatment group and the control group were 70.38 ± 16.32 and 64.4 ± 14.45, respectively. The ESS scores of the treatment group and the control group were 82.4 ± 13.8 and 76.9 ± 13.8 after 1 week, respectively. There was significant difference between the two groups. The treatment group and control group, the onset time compared with the treatment group was significantly earlier than the control group, the difference was statistically significant. Conclusion: Edaravone injection 30 mg intravenously, 2 times / d treatment can effectively improve the acute cerebral infarction neurological deficit and daily living ability, and can well control the progress of cerebral infarction.